Showing 1081-1090 of 9850 results for "".
Dermatology Q&A: New Directions in the Treatment of Hypopigmented Scars
https://practicaldermatology.com/topics/general-topics/dermatology-qa-new-directions-in-the-treatment-of-hypopigmented-scars/21980/A new study shows that off-label use of an unexpected agent yields promising results in the repigmentation of hypopigmented scars.The State of AI in Dermatology
https://practicaldermatology.com/issues/january-february-2025/the-state-of-ai-in-dermatology/32927/The term “artificial intelligence” (AI) has been inescapable since OpenAI released ChatGPT to the public in November 2022.Starting a Systemic Therapy in Atopic Dermatitis or Psoriasis
https://practicaldermatology.com/series/pa-perspectives/Starting-a-Systemic-Therapy-in-Atopic-Dermatitis-or-Psoriasis/26644/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses how to talk to patients about starting a systemic therapy in atopic dermatitis or psoriasis; how to keep the conversation to 7 minutes; and the importance ofBridging the Gap Between Hair Care and Skincare
https://practicaldermatology.com/topics/hair-nails/bridging-the-gap-between-hair-care-and-skincare/23800/Hair care can have an impact on scalp, face, and body skin, which demonstrates the need to consider hair care products’ intersection with the skincare category.A Biologic Test for Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/a-biologic-test-for-cutaneous-squamous-cell-carcinoma/24025/Cutaneous squamous cell carcinoma (cSCC) encompasses a broad spectrum of disease severity, from superficial and easily treatable skin lesions to potentially life-threatening metastatic cancer. Adjuvant radiation therapy (ART) is recommended to reduce the likelihood of relapse following surgical reseChitotriosidase: Providing Confirmation of Sarcoidosis When ACE Fails
https://practicaldermatology.com/topics/clinical-case-reports/chitotriosidase-providing-confirmation-of-sarcoidosis-when-ace-fails/26642/Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE FailsCannabinoid Photo-Rejuvenation: A Clinico-Pathologic Study
https://practicaldermatology.com/topics/feature/cannabinoid-photo-rejuvenation-a-clinico-pathologic-study/29188/In this study, we sought to assess the effectiveness of a novel topical formulation containing CBD isolate, resveratrol, thyme extract, caffeine, and lecithin in reversing photodamage over a 90-day treatment period.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.Understanding and Addressing the Impact of Plaque Psoriasis Among Patients with Skin of Color
https://practicaldermatology.com/topics/psoriasis/understanding-and-addressing-the-impact-of-plaque-psoriasis-among-patients-with-skin-of-color/23763/Patients, physicians, and others are joining together to elevate the level of care for patients with skin of color who develop psoriatic disease.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approve